It is pretty obvious that Merck management is getting ready for winding up the firm's operations. That does not come as a surprise. Most analysts (and media headlines) have been questioning if Merck will survive the Vioxx recall mess. It could have survived if the management was willing to take a more conciliatory approach. In the opinion of iProceed , there are several fundamental flaws with Merck's approach to handing recall of Vioxx: No matter what, you never antagonize your customers (which in this case are patients, and not healthcare companies as Merck might like to believe). By taking a very hostile approach and telling Vioxx customers that something was wrong with them rather than Vioxx, Merck is essentially telling its customers that it doesn't care. As the cases go to trial, a lot of ugly details will come out that will show that Merck knew as early as 2000 that Vioxx was a problematic drug but it continued to aggressively advertise it to consumers, rather than de...
Tips from a freelancer consultant for the benefit of other gig economy and self-employed workers and contractors.